Drug delivery device with air and backflow elimination

Information

  • Patent Grant
  • 11147931
  • Patent Number
    11,147,931
  • Date Filed
    Thursday, November 15, 2018
    6 years ago
  • Date Issued
    Tuesday, October 19, 2021
    3 years ago
Abstract
A wearable drug delivery device that can deliver a liquid drug stored in a container to a patient or user is provided. A soft needle or cannula can be placed in fluid communication with the liquid drug and can be coupled to a needle insertion component that provides access to the patient. A drive system of the drug delivery device can expel the liquid drug from the container to the patient through the soft needle or cannula. The wearable drug delivery device can include components for preventing backflow and eliminating air within the liquid drug. As a result, the comfort of the patient can be enhanced and correct drug dosages can be provided when using the drug delivery device.
Description
TECHNICAL FIELD

Embodiments generally relate to medication delivery. More particularly, embodiments relate to providing flow of a liquid drug from a drug delivery device in a manner that eliminates air entrainment and backflow.


BACKGROUND

Many conventional drug delivery systems, such as handheld auto-injectors, are designed to rapidly deliver a drug to a patient. These conventional drug delivery systems are generally not suitable for delivering a drug to a user over relatively longer periods of time as may be required for many drugs. As an alternative to conventional auto-injectors, many conventional drug delivery systems are designed to be wearable and to deliver a drug more slowly to the patient. While these conventional wearable drug delivery devices provide advantages, they can also suffer from certain problems in operation.


One problem with conventional wearable drug delivery devices is that, under certain circumstances, fluid from the user's body can undesirably be forced back into the fluid path of the drug delivery device. As will be appreciated, during drug delivery using a wearable device, the device and the user's body can be part of a balanced pressure system. Thus, if the pressure in the system is disturbed, undesirable backflow can occur. This, in turn, can cause clogging of the fluid path and/or can result in incorrect dosage to the patient. The problem can be particularly acute when the backflow includes blood, which can coagulate in the fluid delivery path causing the aforementioned clogging, and which, as mentioned, can prevent delivery of the drug and/or incorrect dosage to the patient.


Another problem with conventional wearable drug delivery devices is that, during filling with a liquid drug, there exists the possibility that air bubbles can become trapped in the liquid drug if the user does not properly purge the air. Priming techniques may thus be employed to remove trapped air and also to fill parts of the fluid path with deliverable liquid drug. Trapped air in the fluid path can present problems because air is compressible and can create compliance within a hydraulic drug delivery system. Compliance in the system and compressibility of air due to pressure or temperature can undesirably allow interstitial pressure to migrate bodily fluids, such as blood, into the fluid path and even into the associated liquid drug reservoir. If blood is allowed to migrate into the fluid path, it can coagulate and occlude the flow path, hindering the device's ability to deliver the liquid drug in a desired controlled manner.


In view of the above, it would be desirable to provide a drug delivery device that prevents undesirable backflow of fluids in the drug delivery path, eliminates air from the delivered liquid drug, and ensures uninterrupted delivery of liquid drug to the user.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates an exemplary drug delivery device.



FIG. 2 illustrates a side view of the drug delivery device of FIG. 1.



FIG. 3 illustrates an exemplary system for removing air from a fluid path of the drug delivery device of FIG. 1.



FIG. 4A illustrates a soft needle or cannula of the fluid path of the drug delivery device of FIG. 1 engaged with a user.



FIG. 4B illustrates a tip portion of the soft needle or cannula of FIG. 4A engaged with tissue of a user.



FIG. 4C illustrates a flow sensor system coupled to the fluid path of the drug delivery device of FIG. 1.



FIG. 5 illustrates a technique for preventing coagulation of fluid within the fluid path of the drug delivery device of FIG. 1.





DETAILED DESCRIPTION

This disclosure presents various systems, components, and methods for delivering a liquid drug or medicine to a patient or user. Each of the systems, components, and methods disclosed herein provides one or more advantages over conventional systems, components, and methods.


Various embodiments include a wearable drug delivery device that can deliver a liquid drug stored in a container to a patient or user. A soft needle or cannula can be placed in fluid communication with the liquid drug and can be coupled to a needle insertion component that provides access to the patient. A drive system of the drug delivery device can expel the liquid drug from the container to the patient through the soft needle or cannula. The result is enhanced comfort of the patient when using the drug delivery device. Correct dosage to the patient can also be assured. Any type of liquid drug can be stored by the drug delivery device and delivered to a patient. In various embodiments, the container can contain any therapeutic agent such as, for example, a drug, a subcutaneous injectable, a medicine, or a biologic. Other embodiments are disclosed and described.



FIG. 1 illustrates an exemplary embodiment of a drug delivery device 100. The drug delivery device 100 can include a top portion or cover 102 and a lower portion or base 104. The top portion 102 and the lower portion 104 can together form a housing of the drug delivery device 100. The top portion 102 and the lower portion 104 can be coupled together to form an outside of the drug delivery device 100. The top portion 102 and the lower portion 104 can be formed from any material including, for example, plastic, metal, rubber, or any combination thereof.


The top portion 102 of the drug delivery device 100 can include a raised portion 106 that is elongated and runs along a side of the drug delivery device 100. A liquid drug cartridge (not shown) can be approximately positioned under the raised portion 106 such that the raised portion 106 accommodates the size and positioning of a liquid drug container within the drug delivery device 100. The top portion 102 can also include a patient interaction element or component 108. In various embodiments, the patient interaction element 108 can be a push button or other patient input device used to activate the drug delivery device 100.


The drug delivery device 100 can be a wearable drug delivery device 100. As a wearable device, the drug delivery device 100 can be part of an on-body delivery system (OBDS). The drug delivery device 100 can be coupled to a patient using an adhesive. The drug delivery device 100 can operate as a bolus drug delivery device, or as a continuous drug delivery device. In general, the drug delivery device 100 can provide any amount of a stored liquid drug to a patient over any period of time.



FIG. 2 illustrates a side view of the drug delivery device 100. As shown, the drug delivery device 100 can include a soft needle or cannula 110 extending from the bottom portion 104 of the drug delivery device 100. The soft needle or cannula 110 can be a portion of a needle insertion mechanism. In some embodiments, the soft needle or cannula 110 extends from the drug delivery device 100 into the patient once a hard needle of the needle insertion mechanism has been retracted back inside the drug delivery device 100. The soft needle or cannula 110 can extend below the bottom portion 104 when attached to a patient and when delivering a liquid drug to the patient. In various embodiments, the soft needle or cannula 110 can remain extended outside of the drug delivery device 100 after activation.



FIG. 3 illustrates a system 300 for removing air from a fluid path of the drug delivery device 100. The system 300 can include a fluid path 112 that employs air eliminating features. The system 300 can be a part or component of the drug delivery device 100. The fluid path 112 can couple a reservoir 114 to a patient or user of the drug delivery device 100. As an example, the fluid path 112 can provide fluid communication between the reservoir 114 and the soft needle or cannula 110 used to provide access to the body of the user of the drug delivery device 100. In various embodiments, the reservoir 114 can be a pre-filled cartridge.


The reservoir 114 can store or hold any type of liquid drug 140. As an example, the liquid drug 140 can be insulin. A plunger 142 can be positioned within the reservoir 114. The plunger 142 can be moved to expel the liquid drug 140 from the reservoir 114—by forcing the liquid drug 140 out of the reservoir 114, through the fluid path 112, and on to the soft needle or cannula 110 for delivery to the user. The fluid path 114 can be formed of a variety materials including, for example, plastic, metal, rubber, or any combination thereof. The plunger 142 can be considered to be a pump or pumping system, or a portion thereof, for extracting the liquid drug 140 from the reservoir 114.


It will be appreciated that for purposes of discussion, the term “fluid path” (or fluid path component) may be any portion of a fluid path within, or outside, the drug delivery device 100, which is employed to deliver the liquid drug 140 to a user. In the illustrated embodiment, the fluid path 112 runs from the reservoir 114 within the drug delivery device 100 to the soft needle or cannula 110, which can be located either inside or outside the drug delivery device 100.


As mentioned, the liquid drug 140 within the reservoir 114 and/or fluid path 112 can contain undesirable quantities of air. With conventional devices, such air may be eliminated from a fluid path using a separate priming step. During priming, a quantity of liquid drug from a liquid drug reservoir is ejected from the end of the drug delivery path to eliminate any air bubbles present in the fluid path. Such priming may not be effective, however, at eliminating air bubbles that exist far back in the fluid path (e.g., closer to the reservoir) or within the fluid reservoir. Thus, priming can be ineffective in ensuring that all air bubbles are removed from the reservoir and fluid path.


As shown in FIG. 3, the fluid path 112 can include a venting station or component 118. The venting station 118 can include an opening 144 in a wall of the fluid path 112. The opening can be blocked or covered by a membrane 116. The membrane 116 can comprise a liquid-proof and air-permeable (e.g., hydrophobic) material. The membrane 116 can prevent the liquid drug 140 from passing therethrough, while allowing any air bubbles entrained in the liquid drug 140 to pass therethrough. Specifically, any air or air bubbles within the liquid drug 140 can pass through the membrane 116 as the liquid drug 140 traverses the venting station 118 of the fluid path 112. In doing so, however, the liquid drug 140 is blocked from exiting the fluid path 112 and can be passed along to the soft needle or cannula 110.


In various embodiments, based on the arrangement of the venting station 118 and the fluid path 112 as shown in FIG. 3, when an air bubble enters the venting station 118, the pressure inherent in the system 300 will push the air out through the membrane 116 (while retaining the fluid therein), thus removing air bubbles from the liquid drug 140 in the fluid path 112.


It will be appreciated that the venting station 118 may be implemented at one or more locations along the length of the fluid path 112. In some embodiments, a venting station 118 can be implemented directly adjacent to, or as part of, the reservoir 114 itself.


In some embodiments, the discrete venting station 118 can be eliminated, and the membrane 116 can be directly attached to the fluid path 112 at one or more locations along the length thereof. As an example, the membrane 116 can form a portion of the fluid path 112 (such as a portion of a wall of the fluid path 112). Alternatively, in lieu of the membrane 116, relatively very small channels could be employed in the fluid path 112 itself. The channels can be sized so that they do not allow the liquid drug 140 to flow through (e.g., due to surface tension), but allow air to flow through.


It will be appreciated that with the system 300 and arrangements described in relation thereto, air elimination is automatically performed by the system 300, thereby eliminating the additional priming step which is required to be performed by a user of a conventional device.



FIGS. 4A-4C illustrate arrangements for preventing fluid from flowing back into the fluid path 112. As mentioned, conventional drug delivery devices can, under certain circumstances, allow fluid from the user's body to flow back into a fluid path of a drug delivery device. Backflow can cause undesirable clogging of the fluid path and/or can result in incorrect dosage of liquid drug to the patient. FIG. 4A illustrates the soft needle or cannula 110 of the fluid path 112 engaged with a user. FIG. 4B illustrates a tip portion 120 of the soft needle or cannula 110 engaged with tissue 122 of the user. FIG. 4C illustrates a flow sensor system 402 coupled to the fluid path 112.


As shown in FIG. 4A, the fluid path 112 is shown coupling the reservoir 114 to the tip portion 120 of the soft needle or cannula 110. The tip portion 120 can be engaged with the tissue 122 of a user. The soft needle or cannula 110 can be part of the fluid path 112, which itself is fluidically coupled to the reservoir 114 containing the liquid drug 140 (not shown in FIG. 4A for simplicity).



FIG. 4B shows a close-up view of the tip portion 120 of the soft needle or cannula 110 engaged with the tissue 122 of the user. As shown in FIG. 4B, the tip portion 120 of the soft needle or cannula 110 can have a “duckbill” feature 404 attached to, or otherwise integrated into, the soft needle or cannula 110. The duckbill feature 404 can comprise an opening or slit at approximately a center of the tip portion 120 that can open or close. The duckbill feature 404 can be a one-way valve that can only open with a positive pressure imposed from inside the drug delivery device 100, which in some embodiments can be created by the plunger 142 used to dispense the liquid drug 140. In the event that pressure in the user's body (i.e., tissue pressure) is greater than the pressure in the fluid path 112, the duckbill feature 404 can seal itself (as shown in FIG. 4B) and will not allow fluid to travel back into the fluid path 112.


Alternatives to the duckbill feature 404 can include the use of one or more one-way check valves (e.g., ball valves) and/or alternative tip arrangements that enable flow in one direction but prevent flow in an opposite direction (e.g., allow flow from the fluid path 112 to the tissue 122 of the user but prevent flow from the user into the fluid path 112).



FIG. 4A illustrates the flow sensor system 402 coupled to the fluid path 112. In various embodiments, one or more flow sensor systems can be coupled to the fluid path 112. FIG. 4C shows a close-up view of the flow sensor system 402. The flow sensor system 402 can include a flow sensor 124 positioned to detect the direction of fluid flow through the fluid path 112. If the flow sensor 124 senses that fluid is moving backwards (i.e., from the user to the reservoir 114), then the flow sensor system 402 can activate a “pinch point” to prevent fluid from flowing through the fluid path 112. As shown in FIG. 4C, the pinch point can include a pair of opposing clamping elements 126a and 126b (e.g., as part of the flow sensor system 402), which are positioned on opposite sides of the fluid path 112. In various embodiments, the opposing clamping elements 126a and 126b can be positioned on opposite sides of the soft needle or cannula 110.


The flow sensor system 402 (e.g., via a processor, a controller, or other logic) can, upon receiving signals from the flow sensor 124 indicative of flow moving backwards through the fluid path 112, cause the clamping elements 126a, 126b to move toward each other sufficiently to constrict the fluid path 112, thus preventing flow through the fluid path 112. It will be appreciated that in some embodiments, a mechanical fluid flow detector could be employed in lieu of the flow sensor 124. A mechanical fluid flow detector may be desirable for fully-mechanical implementations of the drug delivery devices 100.



FIG. 5 illustrates an arrangement and/or a technique for preventing coagulation within the fluid path 112 of the drug delivery device 100. As mentioned, coagulation-based clogging of a fluid path can occur when blood flows from a tissue site, back through the fluid path. If the blood is quickly expelled out through the fluid path, coagulation is not an issue. If blood is allowed to remain in the fluid path, however, coagulation can become a problem.


The disclosed arrangement and/or technique can include applying a slow, steady fluid flow (as indicated by flow arrows 502) through the fluid path 112 and out of the soft needle or cannula 110, thus ensuring that blood will not remain in the fluid path 112 long enough to coagulate and block the fluid path.


In such embodiments, a minimum flow rate of about 0.25 microliters per hour of liquid through the fluid path 112 may be employed to ensure that entrained particles 128 are always moving toward the delivery site (i.e., from the reservoir 114 toward the user) and thus cannot coagulate. This flow rate can be controlled either mechanically or electronically, via the pumping arrangement of the drug delivery device 100. This minimum flow rate can be provided by a pumping mechanism (e.g., a plunger) configured to extract a fluid from the reservoir 114.


While certain embodiments of the present invention have been described, it is expressly noted that the present invention is not limited to those embodiments. Rather, the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.

Claims
  • 1. A wearable drug delivery device, comprising: a top portion and a bottom portion;a reservoir between the top portion and the bottom portion and configured to store a liquid drug;a needle insertion component operable to extend a cannula from the bottom portion into a user, anda fluid path component between the top portion and the bottom portion coupling the reservoir to the cannula, the fluid path component configured to enable delivery of the liquid drug to the user of the drug delivery device when the liquid drug is expelled from the reservoir, wherein the fluid path component includes:a venting component, the venting component configured to retain the liquid drug while allowing air within the liquid drug to pass through the venting component and out of the fluid path component.
  • 2. The wearable drug delivery device of claim 1, the venting component comprising an opening within the fluid path component and a membrane covering the opening.
  • 3. The wearable drug delivery device of claim 2, the membrane comprising a liquid-proof and air-permeable material.
  • 4. The wearable drug delivery device of claim 3, the fluid path component comprising an additional venting component positioned directly adjacent to the reservoir.
  • 5. The wearable drug delivery device of claim 3, the fluid path component further includes a flow sensor system.
  • 6. The wearable drug delivery device of claim 5, the flow sensor system comprising a flow sensor, a first clamping component, and a second clamping component.
  • 7. The wearable drug delivery device of claim 6, the flow sensor configured to detect a direction of a flow of the liquid drug in the fluid path component.
  • 8. The wearable drug delivery device of claim 7, the first and second clamping components positioned on opposite sides of the fluid path component.
  • 9. The wearable drug delivery device of claim 8, the first and second clamping components configured to move toward each other to constrict the fluid path component to prevent the flow of the liquid drug in the fluid path component.
  • 10. The drug wearable delivery device of claim 9, the first and second clamping components configured to constrict the fluid path component to prevent the flow of the liquid drug when the flow sensor detects the direction of the flow is from the user toward the reservoir.
  • 11. The wearable drug delivery device of claim 9, the first and second clamping components configured to not constrict the fluid path component to prevent the flow of the liquid drug when the flow sensor detects the direction of the flow is from the reservoir to the user.
  • 12. The drug wearable delivery device of claim 6, the first and second clamping components positioned on opposite sides of the cannula.
  • 13. The wearable drug delivery device of claim 1, the cannula comprising a tip portion having a duckbill feature, the duckbill feature comprising a slit positioned at approximately a center of the tip portion.
  • 14. The wearable drug delivery device of claim 1, the cannula comprising a tip portion having a one-way check valve configured to enable flow of the liquid drug out of the tip portion to the user while preventing flow into the tip portion.
  • 15. The wearable drug delivery device of claim 1, further comprising a pumping system configured to maintain a minimum flow rate of the liquid drug of 0.25 microliters per hour through the fluid path component.
  • 16. The wearable drug delivery device of claim 15, the pumping system comprising a plunger positioned within the reservoir.
  • 17. The wearable drug delivery device of claim 1, wherein the reservoir comprises a pre-filled cartridge.
  • 18. The wearable drug delivery device of claim 17, wherein the liquid drug is insulin.
  • 19. The wearable drug delivery device of claim 1, further comprising: an adhesive to secure the wearable drug delivery device to the user.
  • 20. The wearable drug delivery device of claim 19, wherein: the adhesive is disposed on the bottom portion of the wearable drug delivery device facing the user.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/587,812, filed Nov. 17, 2017, which is incorporated herein by reference in its entirety.

US Referenced Citations (276)
Number Name Date Kind
303013 Horton Aug 1884 A
306691 Johnson Oct 1884 A
315727 Church Apr 1885 A
405524 Benton Jun 1889 A
410817 Weeks, Jr. Sep 1889 A
2667986 Perelson Feb 1954 A
3631847 Hobbs Jan 1972 A
3792703 Moorehead Feb 1974 A
3812843 Wootten May 1974 A
3841328 Jensen Oct 1974 A
3885662 Schaefer May 1975 A
4067000 Carlson Jan 1978 A
4151845 Clemens May 1979 A
4152098 Moody et al. May 1979 A
4193397 Tucker et al. Mar 1980 A
4211998 Junginger et al. Jul 1980 A
4231019 Junginger et al. Oct 1980 A
4261388 Shelton Apr 1981 A
4268150 Chen May 1981 A
4276170 Vaillancourt Jun 1981 A
4342311 Whitney et al. Aug 1982 A
4346385 Schiavone et al. Aug 1982 A
4364385 Lossef Dec 1982 A
4424720 Bucchianeri Jan 1984 A
4435173 Siposs et al. Mar 1984 A
4469481 Kobayashi Sep 1984 A
4475901 Kraegen et al. Oct 1984 A
4498843 Schneider et al. Feb 1985 A
4507115 Kambara et al. Mar 1985 A
4514732 Hayes, Jr. Apr 1985 A
4529401 Leslie et al. Jul 1985 A
4551134 Slavik et al. Nov 1985 A
4559033 Stephen et al. Dec 1985 A
4559037 Franetzki et al. Dec 1985 A
4560979 Rosskopf Dec 1985 A
4562751 Nason et al. Jan 1986 A
4585439 Michel Apr 1986 A
4601707 Albisser et al. Jul 1986 A
4624661 Arimond Nov 1986 A
4634427 Hannula et al. Jan 1987 A
4678408 Nason et al. Jul 1987 A
4684368 Kenyon Aug 1987 A
4685903 Cable et al. Aug 1987 A
4734092 Millerd Mar 1988 A
4743243 Vaillancourt May 1988 A
4755173 Konopka et al. Jul 1988 A
4781688 Thoma et al. Nov 1988 A
4781693 Martinez et al. Nov 1988 A
4801957 Vandemoere Jan 1989 A
4808161 Kamen Feb 1989 A
4836752 Burkett Jun 1989 A
4855746 Stacy Aug 1989 A
4858619 Toth Aug 1989 A
4871351 Feingold Oct 1989 A
4882600 Van de Moere Nov 1989 A
4886499 Cirelli et al. Dec 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
4898579 Groshong et al. Feb 1990 A
4944659 Labbe et al. Jul 1990 A
4969874 Michel et al. Nov 1990 A
4973998 Gates Nov 1990 A
4985016 Theeuwes Jan 1991 A
4994047 Walker Feb 1991 A
5007458 Marcus et al. Apr 1991 A
5045871 Reinholdson Sep 1991 A
5062841 Siegel Nov 1991 A
5109850 Blanco et al. May 1992 A
5125415 Bell Jun 1992 A
5176662 Bartholomew et al. Jan 1993 A
5178609 Ishikawa Jan 1993 A
5189609 Tivig et al. Feb 1993 A
5205819 Ross et al. Apr 1993 A
5213483 Flaherty et al. May 1993 A
5232439 Campbell et al. Aug 1993 A
5239326 Takai Aug 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5245447 Stemmle Sep 1993 A
5254096 Rondelet et al. Oct 1993 A
5257980 Van Antwerp et al. Nov 1993 A
5261884 Stern et al. Nov 1993 A
5281202 Weber et al. Jan 1994 A
5308335 Ross et al. May 1994 A
5312337 Flaherty et al. May 1994 A
5318540 Athayde et al. Jun 1994 A
5342313 Campbell et al. Aug 1994 A
5346476 Elson Sep 1994 A
5364342 Beuchat et al. Nov 1994 A
5411480 Kriesel May 1995 A
5433710 VanAntwerp et al. Jul 1995 A
5452033 Balling et al. Sep 1995 A
5492534 Athayde et al. Feb 1996 A
5503628 Fetters et al. Apr 1996 A
5505709 Funderburk et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5514096 Hiejima May 1996 A
5533389 Kamen et al. Jul 1996 A
5545152 Funderburk et al. Aug 1996 A
5573342 Patalano Nov 1996 A
5575770 Melsky et al. Nov 1996 A
5576781 Deleeuw Nov 1996 A
5582593 Hultman Dec 1996 A
5584813 Livingston et al. Dec 1996 A
5613956 Patterson et al. Mar 1997 A
5630710 Tune et al. May 1997 A
5637095 Nason et al. Jun 1997 A
5643213 McPhee Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5665065 Colman et al. Sep 1997 A
5665070 McPhee Sep 1997 A
5678539 Schubert et al. Oct 1997 A
5685859 Kornerup Nov 1997 A
5693018 Kriesel et al. Dec 1997 A
5695490 Flaherty et al. Dec 1997 A
5702363 Flaherty Dec 1997 A
5704520 Gross Jan 1998 A
5716343 Kriesel et al. Feb 1998 A
5726404 Brody Mar 1998 A
5726751 Altendort et al. Mar 1998 A
5741228 Lambrecht et al. Apr 1998 A
5747350 Sattler May 1998 A
5748827 Holl et al. May 1998 A
5755682 Knudson et al. May 1998 A
5764159 Neftel Jun 1998 A
5776103 Kriesel et al. Jul 1998 A
5779676 Kriesel et al. Jul 1998 A
5785681 Indravudh Jul 1998 A
5785688 Joshi et al. Jul 1998 A
5797881 Gadot Aug 1998 A
5800397 Wilson et al. Sep 1998 A
5800405 McPhee Sep 1998 A
5800420 Gross et al. Sep 1998 A
5810015 Flaherty Sep 1998 A
5814020 Gross Sep 1998 A
5840063 Flaherty Nov 1998 A
5845218 Altschul Dec 1998 A
5848990 Cirelli et al. Dec 1998 A
5848991 Gross et al. Dec 1998 A
5851197 Marano et al. Dec 1998 A
5858005 Kriesel Jan 1999 A
5858239 Kenley et al. Jan 1999 A
5865806 Howell Feb 1999 A
5871470 McWha Feb 1999 A
5875393 Altschul et al. Feb 1999 A
5878539 Grubb Mar 1999 A
5885808 Spooner et al. Mar 1999 A
5886647 Badger et al. Mar 1999 A
5891097 Saito et al. Apr 1999 A
5897530 Jackson Apr 1999 A
5906597 McPhee May 1999 A
5911716 Rake et al. Jun 1999 A
5919167 Mulhauser et al. Jul 1999 A
5921419 Niedospial, Jr. et al. Jul 1999 A
5931814 Alex et al. Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5954058 Flaherty Sep 1999 A
5954694 Sunseri Sep 1999 A
5957890 Mann et al. Sep 1999 A
5957895 Sage et al. Sep 1999 A
5961492 Kriesel et al. Oct 1999 A
5965848 Altschul et al. Oct 1999 A
5983094 Altschul et al. Nov 1999 A
5993423 Choi Nov 1999 A
5997501 Gross et al. Dec 1999 A
6019747 McPhee Feb 2000 A
6024539 Blomquist Feb 2000 A
6050978 Orr et al. Apr 2000 A
6071292 Makower et al. Jun 2000 A
6090092 Fowles et al. Jul 2000 A
6126637 Kriesel et al. Oct 2000 A
6144847 Altschul et al. Nov 2000 A
6152898 Olsen Nov 2000 A
6174300 Kriesel et al. Jan 2001 B1
6190359 Heruth Feb 2001 B1
6200338 Solomon et al. Mar 2001 B1
6206850 ONeil Mar 2001 B1
6244776 Wiley Jun 2001 B1
6244778 Chesbrough Jun 2001 B1
6309370 Ben-Haim et al. Oct 2001 B1
6363609 Pickren Apr 2002 B1
6375639 Duplessie et al. Apr 2002 B1
6475196 Vachon Nov 2002 B1
6520936 Mann Feb 2003 B1
6527744 Kriesel et al. Mar 2003 B1
6569125 Jepson et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6572585 Choi Jun 2003 B2
6666852 Niedospial, Jr. Dec 2003 B2
6699221 Vaillancourt Mar 2004 B2
6740059 Flaherty May 2004 B2
6883778 Newton et al. Apr 2005 B1
7008404 Nakajima Mar 2006 B2
7018360 Flaherty et al. Mar 2006 B2
7025744 Utterberg et al. Apr 2006 B2
7060059 Keith Jun 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7144384 Gorman et al. Dec 2006 B2
7160272 Eyal et al. Jan 2007 B1
7267665 Steil Sep 2007 B2
7291133 Kindler et al. Nov 2007 B1
7303549 Flaherty et al. Dec 2007 B2
7918825 O'Connor et al. Apr 2011 B2
9402950 Dilanni et al. Aug 2016 B2
20010053895 Vaillancourt Dec 2001 A1
20020010423 Gross et al. Jan 2002 A1
20020032374 Holker et al. Mar 2002 A1
20020066715 Niedospial Jun 2002 A1
20020123740 Flaherty et al. Sep 2002 A1
20030163097 Fleury et al. Aug 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040064088 Gorman et al. Apr 2004 A1
20040088224 Mukai May 2004 A1
20040092865 Flaherty et al. May 2004 A1
20040116847 Wall Jun 2004 A1
20040158208 Hiejima Aug 2004 A1
20040203357 Nassimi Oct 2004 A1
20050020980 Inoue et al. Jan 2005 A1
20050187524 Willis et al. Aug 2005 A1
20050203461 Flaherty et al. Sep 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20050258581 Tanaka Nov 2005 A1
20060134323 O'Brien Jun 2006 A1
20060155210 Beckman et al. Jul 2006 A1
20060178633 Garibotto et al. Aug 2006 A1
20060204535 Johnson Sep 2006 A1
20060253085 Geismar et al. Nov 2006 A1
20060282290 Flaherty et al. Dec 2006 A1
20070005018 Tekbuchava Jan 2007 A1
20070025811 Wilhelm Feb 2007 A1
20070112332 Harding et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070129690 Rosenblatt et al. Jun 2007 A1
20070173974 Lin Jul 2007 A1
20070197163 Robertson Aug 2007 A1
20070282269 Carter et al. Dec 2007 A1
20080004515 Jennewine Jan 2008 A1
20080006500 Spahr Jan 2008 A1
20080051738 Griffin Feb 2008 A1
20080065050 Sparks et al. Mar 2008 A1
20080078400 Martens et al. Apr 2008 A1
20080132880 Buchman Jun 2008 A1
20080249508 Lopez et al. Oct 2008 A1
20080287906 Burkholz et al. Nov 2008 A1
20090054866 Teisen-Simony et al. Feb 2009 A1
20090062767 Van Antwerp et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090099521 Gravesen et al. Apr 2009 A1
20090124979 Raymond et al. May 2009 A1
20090198215 Chong et al. Aug 2009 A1
20090299300 Truitt et al. Dec 2009 A1
20100137784 Cefai et al. Jun 2010 A1
20100152658 Hanson et al. Jun 2010 A1
20110054390 Searle et al. Mar 2011 A1
20110054399 Chong et al. Mar 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110166512 Both et al. Jul 2011 A1
20110230833 Landman et al. Sep 2011 A1
20110251509 Beyhan et al. Oct 2011 A1
20110316562 Cefai et al. Dec 2011 A1
20120003093 Lischer et al. Jan 2012 A1
20120003935 Lydon et al. Jan 2012 A1
20120010594 Holt et al. Jan 2012 A1
20120078161 Masterson et al. Mar 2012 A1
20120238851 Kamen et al. Sep 2012 A1
20120277668 Chawla Nov 2012 A1
20130060233 O'Connor et al. Mar 2013 A1
20130178791 Javitt Jul 2013 A1
20130317753 Kamen et al. Nov 2013 A1
20140074033 Sonderegger et al. Mar 2014 A1
20140127048 Diianni et al. May 2014 A1
20140128839 Dilanni et al. May 2014 A1
20140135880 Bumgartner et al. May 2014 A1
20140316379 Sonderegger et al. Oct 2014 A1
20160015891 Papiorek Jan 2016 A1
20160038689 Lee et al. Feb 2016 A1
20160302054 Kimura et al. Oct 2016 A1
20170128664 Diianni et al. May 2017 A1
Foreign Referenced Citations (57)
Number Date Country
19723648 Aug 1998 DE
19920896 Nov 2000 DE
0341049 Nov 1989 EP
0496305 Jul 1992 EP
0763369 Mar 1997 EP
0867196 Sep 1998 EP
0937475 Aug 1999 EP
2397181 Dec 2011 EP
2830499 Feb 2015 EP
875034 Aug 1961 GB
2443261 Apr 2008 GB
200740148 Oct 2007 TW
M452390 May 2013 TW
8101658 Jun 1981 WO
8606796 Nov 1986 WO
9800193 Jan 1998 WO
9801071 Jan 1998 WO
9856293 Dec 1998 WO
9910040 Mar 1999 WO
9956803 Nov 1999 WO
9962576 Dec 1999 WO
0019887 Apr 2000 WO
0029047 May 2000 WO
0029049 May 2000 WO
0030705 Jun 2000 WO
0061215 Oct 2000 WO
0074752 Dec 2000 WO
0078210 Dec 2000 WO
0152727 Jul 2001 WO
0156633 Aug 2001 WO
0172354 Oct 2001 WO
0176684 Oct 2001 WO
2002015954 Feb 2002 WO
0220073 Mar 2002 WO
0226282 Apr 2002 WO
0240083 May 2002 WO
2002068823 Sep 2002 WO
03090509 Nov 2003 WO
2006053007 May 2006 WO
2007064835 Jun 2007 WO
2008024810 Feb 2008 WO
2008133702 Nov 2008 WO
2009098648 Aug 2009 WO
2011095483 Aug 2011 WO
2012045667 Apr 2012 WO
2012108959 Aug 2012 WO
2012134588 Oct 2012 WO
2012134589 Oct 2012 WO
2013078200 May 2013 WO
2013134486 Sep 2013 WO
2013149186 Oct 2013 WO
2013182321 Dec 2013 WO
2014194183 Dec 2014 WO
2015061493 Apr 2015 WO
2015081337 Jun 2015 WO
2016141082 Sep 2016 WO
2017205816 Nov 2017 WO
Non-Patent Literature Citations (21)
Entry
US 5,954,699 A, 09/1999, Jost et al. (withdrawn)
International Search Report and Written Opinion for Application No. PCT/US2017/015601, dated May 16, 2017, 6 pages.
International Search Report and Written Opinion for Application No. PCT/US18/52464, dated Jan. 4, 2019, 14 pages.
International Search Report and Written Opinion for Application No. PCT/US18/18901, dated Aug. 6, 2018, 15 pages.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2018/018901, dated Sep. 6, 2019, 8 pages.
International Preliminary Report on Patentability dated Oct. 9, 2014, issued in PCT Patent Application No. PCT/US2013/034674, 15 pages.
EPO Search Report dated Nov. 11, 2015, received in corresponding Application No. 13768938.6, 7 pgs.
European Patent Office, “Notification of Transmittal of the ISR and the Written Opinion of the International Searching Authority, or the Declaration,” in PCT Application No. PCT/GB2015/050248, dated Jun. 23, 2015, 12 pages.
U.K. Intellectual Property Office, GB Application No. GB 1401591.1, ““Search Report underSection 17(5)”” dated Jul. 9, 2015, 3 pages.
International Preliminary Report on Patentability dated Apr. 9, 2020, issued in PCT Patent Application No. PCT/US2018/052464, 7 pages.
International Search Report for the International Patent Application No. PCT/US03/16640, dated Oct. 3, 2003, 1 page.
User's Guide for Model 508 Insulin Pump, Mini Med, 8/00, 145 pages.
Web-Site Brochure dated Jan. 4, 2000. SOOIL—Homepage. “Portable Insulin Pump”. www.sooil.com/product2.htm.
Web-Site Brochure dated Jan. 4, 2000. SOOIL—Homepage. ““Portable Insulin Pump””.www.sooil.com/product3.htm.
Web-Site Brochure dated Jan. 4, 2000. SOOIL—Homepage. “Portable Insulin Pump”. www.sooil.com/product4.htm.
Web-Site Brochure dated Dec. 20, 1999. “The Animas R-1000 Insulin Pump”. www .animascorp.com/pump f _ s.html.
Web-Site Brochure dated Dec. 20, 1999. ““The Animas R-1000 Insulin Pump”” www.animascorp.com/pump_f_f.html.
Web-Site Brochure dated Jan. 4, 2000. SOOIL—Homepage. ““Ponable Insulin Pump””.www.sooil.com/intro2.htm.
Web-Site Brochure dated Jan. 4, 2000. MiniMed 508. “Doing its job. Naturally.” www.minimed.com/tiles/mm 113.htm.
Web-Site Brochure dated Dec. 20, 1999. Applied Medical Technology.⋅““508 Pump Information””. www.applied-medical.co.uk/508.htm.
Web-Site Brochure dated Jan. 4, 2000. ““The Glucose Sensor””.www.animascorp.com/sensor f.html.
Related Publications (1)
Number Date Country
20190151568 A1 May 2019 US
Provisional Applications (1)
Number Date Country
62587812 Nov 2017 US